Udenyca, the biosimilar approved by the FDA last week, is used to decrease the incidence of infection by helping the body make white blood cells after receiving cancer medications. Coherus will launch the drug Jan. 3.
Neulasta has a list price of $6,231 per unit, driving Amgen’s sales of the drug to $4.53 billion in 2017.
This is the second biosimilar of Neulasta launched: Mylan’s biosimilar, Fulphila, was approved earlier this year.
More articles on pharmacy:
CVS Health posts $1.4B profit, expects Aetna deal to close by Thanksgiving
Takeda inches closer to $62B takeover of Shire
Massachusetts drugmaker will cut 60% of workforce after failed drug trial
